Koers Newron Pharmaceuticals SpA CBOE EUROPE EQUITIES
Aandelen
0QOI
IT0004147952
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- CHF | - |
|
Omzet 2024 * | 36,98 mln. 39,61 mln. 35,59 mln. | Omzet 2025 * | 27,02 mln. 28,94 mln. 26 mln. | Marktkapitalisatie | 158 mln. 169 mln. 152 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 15 mln. 16,07 mln. 14,44 mln. | Nettowinst (verlies) 2025 * | 5 mln. 5,36 mln. 4,81 mln. | EV/omzet 2024 * | 4,87 x |
Nettoschuld 2024 * | 22,05 mln. 23,62 mln. 21,22 mln. | Nettoliquiditeiten 2025 * | 7 mln. 7,5 mln. 6,74 mln. | EV/omzet 2025 * | 5,59 x |
K/w-verhouding 2024 * |
10,1
x | K/w-verhouding 2025 * |
28,9
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,57% |
Recentste transcriptie over Newron Pharmaceuticals SpA
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 15-05-12 |
Luca Benatti
FOU | Founder | 63 | 01-01-98 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01-01-02 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 78 | 01-01-08 | |
Luca Benatti
FOU | Founder | 63 | 01-01-98 |
Ulrich Köstlin
CHM | Chairman | 71 | 01-01-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,99% | 95,18 mld. | |
-4,34% | 37,55 mld. | |
+75,79% | 28,2 mld. | |
-14,61% | 15,63 mld. | |
-3,46% | 13,63 mld. | |
-12,31% | 11,5 mld. | |
+184,77% | 10,81 mld. | |
-54,13% | 9,23 mld. | |
+6,22% | 9,09 mld. |
- Beurs
- Aandelen
- Koers NWRN
- Koers 0QOI